A Requirement for Cyclin-Dependent Kinase 6 in Thymocyte Development and TumorigenesisMiaofen G. Hu, Philip W. Hinds, Amit Deshpande et al.|Cancer Research|2009Cited by 115
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal Shah, Olalekan O. Oluwole, Ryan D. Cassaday et al.|Leukemia|2025Cited by 35
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal Shah, Armin Ghobadia, Ryan D. Cassaday et al.|Journal for ImmunoTherapy of Cancer|2023Cited by 33
Investigating the Influence of Covariates on Axicabtagene Ciloleucel (axi-cel) Kinetics in Patients with Non-Hodgkin’s LymphomaMagali Chartier, Rhine R. Shen, Simone Filosto et al.|Clinical Pharmacokinetics|2024Cited by 5
Tumor gene expression signatures associated with outcome in large B−cell lymphoma treated with CD19-directed CAR T−cell therapy (axicabtagene ciloleucel)Yuan Tian, Simone Filosto, Justin A. Budka et al.|Frontiers in Oncology|2025Cited by 2